The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial.
 
Lu Xie
No Relationships to Disclose
 
Wei Guo
No Relationships to Disclose
 
Jie Xu
No Relationships to Disclose
 
Xin Sun
No Relationships to Disclose
 
Kuisheng Liu
No Relationships to Disclose
 
Bingxin Zheng
No Relationships to Disclose
 
Ting Ren
No Relationships to Disclose
 
Yi Huang
No Relationships to Disclose
 
Xiaodong Tang
No Relationships to Disclose
 
Taiqiang Yan
No Relationships to Disclose
 
Rongli Yang
No Relationships to Disclose
 
Kunkun Sun
No Relationships to Disclose
 
Danhua Shen
No Relationships to Disclose
 
Yuan Li
No Relationships to Disclose